Combination of rapamycin and picibanil for the treatment of tumo

Drug – bio-affecting and body treating compositions – Plural fermentates of different origin

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 3500

Patent

active

044016530

ABSTRACT:
Described is a method of using a combination of rapamycin and picibanil for the treatment of transplantable carcinogenic tumors.

REFERENCES:
patent: 3477914 (1969-11-01), Okamota et al.
patent: 3632746 (1972-01-01), Kono et al.
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3993749 (1976-11-01), Sehgal et al.
C. Vezina et al., J. Antibiot., 28, 721 (1975).
S. N. Sehgal et al., J. Antibiot., 28, 727 (1975).
H. Baker et al., J. Antibiot., 31, 539 (1978).
R. R. Martel et al., Can. J. Physiol. Pharmacol., 55, 48 (1977).
T. Aoki et al., J. Natl. Cancer Inst., 56, 687 (1976).
An English translation of I. Kimura, Gan-to-Kagaku-Ryoho (Cancer and Chemotherapy), 2, 21 (1975).
An English translation of T. Hattori, J. Japan Soc. Cancer Therapy, 9, 381 (1974).
An English translation of I. Kimura et al., Gan-no-Rinsho (Japan J. Cancer Clin.) 18,886 (1972).
Host Defense Stimulator, Anti-Tumor Str. Pyogenes Preparation, Picibanil (OK-432), Chugai Pharmaceutical Co. Ltd., Tokyo, Japan, 1975.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Combination of rapamycin and picibanil for the treatment of tumo does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination of rapamycin and picibanil for the treatment of tumo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of rapamycin and picibanil for the treatment of tumo will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-905559

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.